P641: Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patientsECCO’23 CopenhagenYear: 2023
Authors: Les, A.(1)*;Cotruta, B.(1);Iacob , R.(1,2);Saizu, R.(1,2);Gheorghe, L.(1,2);Gheorghe, C.(1,2);
(1)Fundeni Clinical institute, Gastroenterology, Bucharest, Romania;(2)“Carol-Davila” University of Medicine and Pharmacy, Gastroenterology, Bucharest, Romania;
P642: Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Chahal, J.(1);Sriranganathan, D.(2);Poo, S.(3);Lo, S.W.(4)*;Kashkooli, S.(4);Garg, M.(4,5);Segal, J.P.(4,5);
(1)Lewisham and Greenwich NHS Trust, Surgery, Lewisham, United Kingdom;(2)Whipps Cross University Hospital, Gastroenterology, London, United Kingdom;(3)Hillingdon Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Northern Hospital Epping, Gastroenterology, Melbourne, Australia;(5)University of Melbourne, Medicine, Melbourne, Australia;
P643: Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort studyECCO’23 CopenhagenYear: 2023
Authors: Sanz Segura, P.(1)*;Gomollón, F.(2);García García, S.(3);Vela, M.(4);Fernández-Clotet, A.(5);Muñoz, R.(6);García de la Filia, I.(7);García Prada, M.(8);Ferrer Rosique, J.A.(9);García, M.J.(10);de Francisco, R.(11);Arias, L.(12);Barrio, J.(13);Guerra, I.(14);Ponferrada Diaz, A.(15);P. Gisbert, J.(16);Carrillo-Palau, M.(17);Calvet, X.(18);Márquez-Mosquera, L.(19);Gros, B.(20);Cañete, F.(21);Monfort, D.(22);Madrigal, R.E.(23);Roncero, O.(24);Laredo, V.(2);Montoro, M.(25);Muñoz, C.(26);López-Cauce, B.(27);Lorente, R.(28);Fuentes, A.(29);Vega, P.(30);Martín, D.(31);Nerín de la Puerta, J.(1);Varela, P.(32);Casas-Deza, D.(33);Martínez, P.(34);Pajares, R.(35);J. Lucendo, A.(36);Domènech, E.(21);García-López, S.(33);
(1)Hospital Royo Villanova, Gastroenterology Department, Zaragoza, Spain;(2)Hospital Clínico Universitario Lozano Blesa, Gastroenterology Department, Zaragoza, Spain;(3)Hospital Universitario La Fe, Gastroenterology Department, Valencia, Spain;(4)Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(5)Hospital Clinic de Barcelona, Gastroenterology Department, Barcelona, Spain;(6)Hospital General Universitario Dr Balmis, Gastroenterology Department, Alicante, Spain;(7)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(8)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(9)Hospital Fundación Alcorcón, Gastroenterology Department, Madrid, Spain;(10)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology and Hepatology Department, Santander, Spain;(11)Hospital Universitario Central de Asturias, Gastroenterology Department, Oviedo, Spain;(12)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(13)Hospital Universitario Río Hortega, Gastroenterology Department, Valladolid, Spain;(14)Hospital Universitario de Fuenlabrada, Gastroenterology Department, Madrid, Spain;(15)Hospital Universitario Infanta Leonor, Gastroenterology Department, Madrid, Spain;(16)Hospital Universitario de La Princesa, Gastroenterology Department, Madrid, Spain;(17)Hospital Universitario de Canarias, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(18)Corporació Sanitaria Parc Taulí, Gastroenterology Department, Sabadell, Spain;(19)Hospital del Mar, Servei de Digestiu, Barcelona, Spain;(20)Hospital Universitario Reina Sofía, Gastroenterology Department, Córdoba, Spain;(21)Hospital Universitari Germans Trials i Pujol and CIBERehd, Gastroenterology Department, Barcelona, Spain;(22)Consorci Sanitari de Terrassa, Gastroenterology Department, Terrasa, Spain;(23)Hospital Clínico Universitario de Valladolid, Gastroenterology Department, Valladolid, Spain;(24)Hospital General La Mancha Centro, Gastroenterology Department, Ciudad Real, Spain;(25)Hospital San Jorge, Gastroenterology Department, Huesca, Spain;(26)Hospital de Basurto, Gastroenterology Department, Bilbao, Spain;(27)Hospital General Universitario Gregorio Marañón, Gastroenterology Department, Madrid, Spain;(28)Hospital General de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(29)Hospital Virgen de La Concha- Complejo Asistencial de Zamora, Gastroenterology Department, Zamora, Spain;(30)Complejo Hospitalario Universitario de Ourense, Gastroenterology Department, Ourense, Spain;(31)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(32)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijón, Spain;(33)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(34)Hospital 12 de Octubre, Gastroenterology Department, Madrid, Spain;(35)Hospital Infanta Sofía, Gastroenterology Department, Madrid, Spain;(36)Hospital General de Tomelloso, Gastroenterology Department, Ciudad Real, Spain;on behalf of the ENEIDA project of GETECCU
P644: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate small intestinal mucosal healing in asymptomatic CRP-negative Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
(1)Kagoshima University Graduate School of Medical and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima city, Japan;
P645: Use of Leukocytapheresis in inflammatory bowel disease in paediatric patients. A serie of 10 cases.ECCO’23 CopenhagenYear: 2023
Authors: Martinez Navarro, G.(1)*;Palomino Pérez, L.M.(1);Velasco Rodríguez-Belvís, M.(1);Cañedo Villarroya, E.(1);De la Mano Hernández, A.(1);Dominguez Ortega, G.(1);Martínez Pérez, J.(1);Martín Fernández, C.(1);Di Campli Zaghlul, M.(1);García Hernández, P.(1);Sánchez Llorente, P.(1);Muñoz Codoceo, R.A.(1);
(1)Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition, Madrid, Spain;
P646: Relative association of bowel urgency clinically meaningful improvement and bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Work Productivity and Activity Impairment Scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 Phase 3 clinical trials.ECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Feagan, B.G.(2,3);Gibble, T.H.(4);Keohane, A.(4);Eastman, W.J.(4);Traxler, K.A.(4);Schreiber, S.(5);Jairath, V.(2);Armuzzi, A.(6);
(1)Icahn School of Medicine, Gastroenterology, New York, United States;(2)Western University, Epidemiology & Biostatistics, London- Ontario, Canada;(3)Alimentiv Inc., Epidemiology & Biostatistics, London- Ontario, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)University Hospital Schleswig-Holstein- Kiel University, Department Internal Medicine, Kiel, Germany;(6)Humanitas Research Hospital, Gastroenterology, Milan, Italy;
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Almas, S.(1);Al-Talib, I.(1)*;Rahman, C.(1);Ansari, M.(1);Jones, J.(1);Slater, J.(1);King, D.(1);De Silva, S.(1);
(1)Russells Hall Hospital, Gastroenterology, Dudley, United Kingdom;
P649: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Carbery, I.(1)*;Lin, S.(2);Chanchlani, N.(2);Janjua, M.(2);Nice, R.(3);McDonald, T.J.(3);Bewshea, C.(4);Kennedy, N.A.(2);Ahmad, T.(2);Goodhand, J.R.(2);Selinger, C.P.(1);
(1)Leeds Teaching Hospitals NHS Trust, Leeds Gastroenterology Institute, Leeds, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(4)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;
P650: Integrin expression patterns of patients with IBD treated with vedolizumab.ECCO’23 CopenhagenYear: 2023
Authors: Kokkotis, G.(1)*;Chalakatevaki, K.(1);Papathanasiou, E.(2);Tzanoudaki, M.(3);Kane, R.(3);Liatsis, M.(3);Zampeli, E.(2);Michopoulos, S.(2);Bamias, G.(1);
(1)3rd Academic Department of Internal Medicine- University of Athens- Sotiria Hospital, GI Unit, Athens, Greece;(2)Alexandra General Hospital, Gastroenterology Department, Athens, Greece;(3)"Aghia Sophia" Children's Hospital, Department of Immunology & Histocompatibility, Athens, Greece;
P651: Comparison of Adverse Events of SARS-CoV-2 Vaccination between Patients with Inflammatory Bowel Disease and Healthcare WorkersECCO’23 CopenhagenYear: 2023
Authors: Kim, J.(1)*;Sagong, M.(1);Lee, Y.J.(1);Kim, K.O.(2);Kim, E.S.(3);Kim, E.Y.(4);Jang, B.I.(2);
(1)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(2)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(3)Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(4)Daegu Catholic University of School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;
P652: Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response.ECCO’23 CopenhagenYear: 2023
Authors: Mínguez, A.(1)*;Bastida, G.(1);Terol, I.(1);Argumánez, V.(1);Iborra, M.(1);Aguas, M.(1);Moret, I.(2);Cerrillo, E.(1);Garrido, A.(1);Tortosa, L.(1);Nos, P.(1);
(1)La Fe University and Polytechnic Hospital, Gastroenterology Department, Valencia, Spain;(2)La Fe University and Polytechnic Hospital, IIS Hospital la Fe. IBD research group, Valencia, Spain;
P653: Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Fernandes, S.R.(1,2)*;Bernardo, S.(1,2);Rita Gonçalves, A.(1,2);Moura dos Santos, P.(1,2);Valente, A.(1,2);Tato Marinho, R.(1,2);Correia, L.(1,2);
(1)Hospital Santa Maria - Centro Hospitalar Universitário de Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal;(2)Clinica Universitária de Gastrenterologia, Faculdade de Medicina de Lisboa, Lisboa, Portugal;
P654: Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensusECCO’23 CopenhagenYear: 2023
Authors: Gonzalez Lama, Y.(1)*;Ricart, E.(2);Carpio, D.(3);Bastida, G.(4);Ceballos, D.(5);Ginard, D.(6);Marín-Jimenéz, I.(7);Menchén, L.(8);Muñoz, F.(9);
(1)Hospital Universitario Puerta de Hierro- Majadahonda, Gastroenterology Department, Madrid, Spain;(2)Hospital Clínic de Barcelona, Inflammatory Bowel Disease Unit, Barcelona, Spain;(3)Complexo Hospitalario Universitario de Pontevedra, Gastroenterology Department, Pontevedra, Spain;(4)La Fe University and Polytechnic Hospital, Gastroenterology Department, Valencia, Spain;(5)Hospital Universitario Doctor Negrin, Gastroenterology Department, Las Palmas de Gran Canaria, Spain;(6)Hospital Universitario Son Espases, Gastroenterology Department, Palma de Mallorca, Spain;(7)Hospital Universitario Gregorio Marañón, Gastroenterology Department- Departamento de Medicina- Facultad de Medicina- Universidad Complutense de Madrid, Madrid, Spain;(8)Hospital General Universitario-Insitituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology Department- Departamento de Medicina- Facultad de Medicina- Universidad Complutense de Madrid, Madrid, Spain;(9)Hospital Universitario de Salamanca, Gastroenterology Department, Salamanca, Spain;
P655: MadCAM1 Negativity of Lamina Propria Endothelial Cells is Associated with Non-Response to Vedolizumab in Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Berakova, K.(3);Kadleckova, B.(1);
(1)Nemocnica Bory - Penta Hospitals, Department of Gastroenterology, Bratislava, Slovakia;(2)Nemocnica Bory - Penta Hospitals, Department of Surgery, Bratislava, Slovakia;(3)Martinske Biopticke Centrum, Department of Pathology, Zilina, Slovakia;
P656: Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn's disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyECCO’23 CopenhagenYear: 2023
Authors: Chetwood, J.(1,2)*;Ko, Y.(1);Pudipeddi, A.(1,2);Kariyawasam, V.(3);Paramsothy, S.(1,2);Leong, R.(1,2);
(1)Concord Repatriation General Hospital, Gastroenterology, Sydney, Australia;(2)University of Sydney, Medicine and Health, Sydney, Australia;(3)Blacktown hospital, Gastroenterology, Sydney, Australia;
P657: Current landscape of the real-world utilization of Interleukins 22, 23 and Interleukin 22 binding protein as biomarkers for Inflammatory Bowel Disease (IBD): A targeted literature reviewECCO’23 CopenhagenYear: 2023
Authors: Dolin, P.(1)*;Evans, K.(2);Castañeda, J.(3);Udayachalerm, S.(2);Cabrera, C.(4);
(1)Astrazeneca, Medical & Payer Evidecne, Cambridge, United Kingdom;(2)Evidera, Real-World Evidence, Waltham- MA, United States;(3)Evidera, Real-World Evidence, Paris, France;(4)Astrazeneca, Real-World Science & Analytics, Mölndal, Sweden;
P658: Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect ComparisonECCO’23 CopenhagenYear: 2023
Authors: Reinisch, W.(1)*;Tran, J.(2,3);Patel, K.(4);Borruel, N.(5);Melmed, G.Y.(6);Wegrzyn, L.(3);Levy, G.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panaccione, R.(7);
(1)Medical University of Vienna, n/a, Wien, Austria;(2)University of Washington, The Comparative Health Outcomes- Policy- and Economics Institute, Seattle, United States;(3)AbbVie Inc., n/a, Chicago, United States;(4)St. George's University Hospital, NHS Foundation Trust, London, United Kingdom;(5)Hospital Vall d'Hebron, Crohn's and Colitis Attention Unit- Digestive System Service, Barcelona, Spain;(6)Cedars-Sinai Medical Center, n/a, Los Angeles, United States;(7)University of Calgary, Department of Gastroenterology and Hepatology, Calgary, Canada;
P659: Continuing or stopping 5-aminosalicylate in patients with Inflammatory Bowel Disease under anti-TNF therapy: A nationwide population-based studyECCO’23 CopenhagenYear: 2023
Authors: Seo, J.(1)*;Kim, S.(2);Song, S.(1);Shin, S.H.(1);Park, S.(1);Hong, S.W.(1);Hwang, S.W.(1,3);Park, S.H.(1,3);Yang, D.H.(1);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,3);Kim, Y.J.(2);Ye, B.D.(1,3);
(1)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology, Seoul, Korea- Republic Of;(2)Asan Medical Center- University of Ulsan College of Medicine, Clinical Epidemiology and Biostatistics, Seoul, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P660: Body composition and health-related quality of life in adult Crohn's Disease during clinical remission: The INTICO2 cohort studyECCO’23 CopenhagenYear: 2023
Authors: McDonnell, M.(1,2)*;Sartain , S.(1);Westoby , C.(3);Katarachia, V.(3);Davis, C.(4);Cummings, F.(1);Wootton, S.(2);
(1)University Hospital Southampton, Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)University Hospital Southampton, Department of Nutrition and Dietetics, Southampton, United Kingdom;(4)University Hospital Southampton, Clinical Informatics Research Unit, Southampton, United Kingdom;
